Harvard public health expert warns on gray-market BPC-157 and TB-500 sales
S. Bryn Austin says vials sold as research chemicals carry no assurance of identity or purity, with risks from infection to liver injury.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 1 15:24 ETSource: Harvard T.H. Chan School of Public Health
The wire
- 01Harvard T.H. Chan professor S. Bryn Austin names BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin as peptides pushed by influencers without FDA approval or rigorous clinical testing.
- 02Austin says gray-market and research-chemical suppliers face virtually no government oversight, and cites injection-site and systemic infection, gastrointestinal effects, cardiac abnormalities, liver injury and death among reported harms.
- 03She contrasts these with semaglutide, which she describes as widely tested, prescription-only and still under peer-reviewed study; the piece is an expert Q&A, not new data.
From the source
Read at hsph.harvard.eduPeptides are all over social media and the news. Here’s what to know about them.
On social media, in gossip columns, and in news headlines, synthetic peptides are being touted for their ability to do things like boost athletic performance and muscle growth, increase fat loss, and enhance sexual function. But are these claims true? And are peptides safe? S. Bryn Austin , professor in the Department of Social and Behavioral Sciences at Harvard T.H. Chan School of Public Health a
